Humoral IgG1 responses to tumor antigens underpin clinical outcomes in immune checkpoint blockade.
Gonzalez-Kozlova E, Sweeney R, Figueiredo I, Tuballes K, Ozbey S, Hamon P, Park MD, Ioannou G, Nose Y, Guo R, Restrepo P, Buckup M, Roudko V, Hennequin C, Le Berichel J, Venturini N, Halasz L, Troncoso L, Tabachnikova A, Chang C, Reid A, Brown H, Chin T, Cabal R, Mattiuz R, Eikawa S, Del Valle DM, Gonsalves TR, LaMarche NM, Jamal H, Lansky A, Yi N, Nelson D, Morgenroth-Rebin J, Merand R, Villagomez B, D'Souza D, Radkevich E, Nie K, Chen Z, Tada Y, Nishikawa H, Ward SC, Fiel MI, Brody R, Tabrizian P, Gunasekaran G, Kamphorst AO, Cohen N, Curotto de Lafaille M, Hapanowicz O, Lucas N, Wu K, James N, Lin JC, Thurston G, Schwartz M, Fiaschi N, Kim-Schulze S, Merad M, Marron TU, Gnjatic S.
Gonzalez-Kozlova E, et al. Among authors: gnjatic s.
Nat Med. 2026 Jan 27. doi: 10.1038/s41591-025-04177-6. Online ahead of print.
Nat Med. 2026.
PMID: 41593194